Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control

References

• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7:11.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
   PubMed Web of Science ®Google Scholar
• Shah UM, Safri SNA, Thevadas R, et al. COVID-19 outbreak in Malaysia: actions taken be the Malaysian government. Int J Infect Dis. 2020;97. DOI:10.1016/j.ijid.2020.05.093.
   Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W-L, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
   PubMed Web of Science ®Google Scholar
• Kraemer MUG, Yang C-H, Gutierrez B, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science. 2020;368:493–497.
   PubMed Web of Science ®Google Scholar
• Sun J, He W-T, Wang L, et al. COVID-19: epidemiology, evolution and cross-disciplinary perspectives. Trends Mol Med. 2020;26:483–495.
   PubMed Web of Science ®Google Scholar
• Saglietto A, D’Ascenzo F, Zoccai GB, et al. COVID-19 in Europe: the Italian lesson. Lancet. 2020;395:1110–1111.
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Remuzzi G. Covid-19 and Italy: what next. Lancet. 2020;395:1225–1228.
   PubMed Web of Science ®Google Scholar
• Lillie PJ, Samson LA, Li A, et al. Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission. J Infect. 2020;80:600–601.
   Web of Science ®Google Scholar
• Jarvis CI, Van Zandvoort K, Gmma A, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Med. 2020;18:124.
   PubMed Web of Science ®Google Scholar
• Mahse E. Covid-19: UK could delay non-urgent care and call doctors back from leave and retirement. BMJ. 2020;368:m854.
   PubMedGoogle Scholar
• Moghadas S, Shoukat A, Fitzpatrick MC, et al. Projecting hospital utilization during the COVID-19 outbreaks in the United States. PNAS. 2020;117:9122–9126. www.pnas.org/cgi/doi/10.1073/pnas.2004064117
   PubMed Web of Science ®Google Scholar
• Burke RM, Midgely CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19 – United States. MMWR Morb Mortal Wkly Rep. 2020;69:245–246.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. COVID-19 situation update for the EU/EEA and the UK, as of 7th September 2020; [cited 2020 Aug 9]. Available from: https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea.
   Google Scholar
• Richie H, Oritiz-Ospina B. Our world in data 2020, Oxford University; [cited 2020 Sept 7]. Available from: https://ourworldindata.org/coronavirus..
   Google Scholar
• Wang C, Liu Z, Chen Z, et al. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol. 2020;92:667–674.
   Web of Science ®Google Scholar
• Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372.
   PubMed Web of Science ®Google Scholar
• Shereen MA, Khan S, Kazmi A, et al. Covid-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91.
   PubMed Web of Science ®Google Scholar
• SIB Swiss Institute of Bioinformatics. Structural diagram of SARS-CoV and MERS. Viral zone; 2020 [cited 2020 Aug 15]. Available from: https://www.sib.swiss/.
   Google Scholar
• Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613–620.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127–20.
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation and treatment coronavirus (COVID-19). In: StatPearls [Internet] eds. Treasure Island (FL): StatPearls Publishing, 2020. PMID: 32150360.
   Google Scholar
• Tok TT, Tatar G. Structures and functions of coronavirus proteins: molecular modeling of viral nucleoprotein. Int J Virol Infect Dis. 2017;2:001–007.
   Google Scholar
• Sharma R, Agarwal M, Gupta M, et al. Coronavirus disease 2019 (COVID-19). In: Saxena S, editor. Medical virology: from pathogenesis to disease control. Springer: Singapore. 2020. 55–70. DOI:10.1007/978-981-15-4814-7_6
   Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
   PubMedGoogle Scholar
• Aiping W, Peng Y, Baoying H, et al. Genome composition and divergence of the novel coronavirus (Covid-19). Cell Host Microbe. 2020;27:325–328.
   PubMed Web of Science ®Google Scholar
• Yan-Hua L, Gao H, Xiao Y et al. Bioinformatic analysis on potential anti viral targets against a spike protein of MERS. 2018 9th International Conference on Information Technology in Medicine and Education (ITME); 2018; Hangzhou. p. 67–71.
   Google Scholar
• Masters PS, Kuo L, Ye R, et al. Genetic and molecular biological analysis of protein-protein interactions in coronavirus assembly. Adv Exp Med Biol. 2006;581:163.
   PubMed Web of Science ®Google Scholar
• Wang M, Ludwig K, Böttcher C. The role of stearate attachment to the hemaglutinin-esterase-fusion glycoprotein HEF of influenza C virus. Cell Microbiol. 2016;18:692–704.
   PubMed Web of Science ®Google Scholar
• De Groot RJ. Structure, function and evolution of the hemaglutinin-esterase proteins of corona and toroviruses. Glycoconj J. 2006;23:59–72.
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577–582.
   PubMed Web of Science ®Google Scholar
• Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun. 2020;87:53–54.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8:750–752.
   PubMed Web of Science ®Google Scholar
• George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–815.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Golenbock D, Latz E, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer’s Res Ther. 2020;12. DOI:10.1186/s13195-020-00640-3.
   Web of Science ®Google Scholar
• Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268–2270.
   PubMed Web of Science ®Google Scholar
• Bindoli S, Felicetti M, Sfriso P, et al. The amount of cytokine-release defines different shades of Sars-Cov2 infection. Exp Biol Med. 2020;245:970–976.
   Web of Science ®Google Scholar
• Garcia-Borrega J, Goedel P, Ruger MA, et al. In the eye of the storm: immune- mediated toxicities associated with CAR-T cell therapy. Hemisphere. 2019;3:e191.
   Google Scholar
• Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10:102–108.
   Web of Science ®Google Scholar
• Reghunathan R, Jayapal M, Hsu LY, et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol. 2005;6:2.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Zhan Y, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72:4410–4415.
   PubMed Web of Science ®Google Scholar
• Nicholls J, Dong XP, Jiang G, et al. SARS: clinical virology and pathogenesis. Respirology. 2003;8:S6–8.
   PubMed Web of Science ®Google Scholar
• Mock JR, Tune MK, Dial CF, et al. Effects of IFN-c on immune cell kinetics during the resolution of acute lung injury. Physiol Rep. 2020;8:e14368.
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, King LS, D’Alessio F. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol. 2014;306:L709–25.
   PubMed Web of Science ®Google Scholar
• Bos LD, Schouten LR, van Vught LA, et al. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax. 2017;72:876–883.
   PubMed Web of Science ®Google Scholar
• Loke YK, Heneghan C. Why no one can ever recover from COVID-19 in England – a statistical anomaly. July 16th 2020. The centre for evidence-based medicine. University of Oxford; [cited 2020 Aug 9]. Available from: https://www.cebm.net/covid-19/.
   Google Scholar
• Hale T, Webster S, Petherick A et al. Oxford COVID-19 Government Response Tracker. Blavatnik School of Government, Oxford University; [cited 2020 Aug 9]. Available from: https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker.
   Google Scholar
• Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Eng J Med. 2020;382:1199–1207. .
   Web of Science ®Google Scholar
• Liu Y, Bayle AA, Wilder-Smith A, et al. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:taaa021. .
   PubMed Web of Science ®Google Scholar
• Linka K, Peirlinck M, Kuhl E. The reproduction number of COVID-19 and its correlation with public health interventions. medRxiv. 2020. DOI:10.1101/2020.05.01.20088047
   Google Scholar
• Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. BMJ. 2020b;369:m1327.
   PubMedGoogle Scholar
• Population Pyramids of the World 1950–2100. [accessed 2020 Sep 15]. Available from: https://www.populationpyramid.net/singapore/2020/
   Google Scholar
• Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. Preprints. 2020;2020020051. DOI:10.20944/preprints202002.0051.v2
   Google Scholar
• Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26:767–772.
   PubMed Web of Science ®Google Scholar
• Gao F, Zheng KI, Wang X-B, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020;43:e72–e74.
   PubMed Web of Science ®Google Scholar
• Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.
   PubMed Web of Science ®Google Scholar
• Pareek M, Bangash MN, Pareek N, et al. Ethnicity and COVID-19: an urgent public health research priority. Lancet. 2020;395:1421–1422.
   PubMed Web of Science ®Google Scholar
• Aldridge RW, Lewer D, Katikireddi SV, et al. Black, Asian and minority ethnic groups in England are at increased risk of death from COVID-19: indirect standardization of NHS mortality data. Wellcome Open Res. 2020;5:88.
   PubMedGoogle Scholar
• Patel P, Hiam L, Sowemimo A, et al. Ethnicity and covid-19. Public health England’s review of disparities in covid-19 is a serious missed opportunity. BMJ. 2020;369:m2282.
   PubMedGoogle Scholar
• Khunti K, Singh AK, Pareek M, et al. Is ethnicity linked to incidence or outcomes of covid-19? BMJ. 2020;369:m1548.
   PubMed Web of Science ®Google Scholar
• Kirby T. Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities. Lancet Respir Med. 2020;8:547–548.
   PubMed Web of Science ®Google Scholar
• Saini A. Stereotype threat. Lancet. 2020;395:164–165.
   Google Scholar
• Khuroo MS, Khuroo M, Khuroo MS, et al. COVID-19 vaccines: a race against time in the middle of death and devastation. J Clin Exp Hepatol. 2020. DOI:10.1016/j.jceh.2020.06.003
   Web of Science ®Google Scholar
• Guo G, Ye L, Pan K, et al. New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention. Front Cell Dev Biol. 2020;8. DOI:10.3389/fcell.2020.00410.
   Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;19:4773–4779.
   Web of Science ®Google Scholar
• Wu D, Koganti R, Lambe UP, et al. Vaccines and therapies in development for SARS-CoV-2 infections. J Clin Med. 2020;9:1885.
   PubMed Web of Science ®Google Scholar
• Uddin M, Mustafa F, Rizvi TA, et al. SARS-CoV-2/COVID-19: viral genomics, epidemiology, vaccines, and therapeutic interventions. Viruses. 2020;12:526.
   PubMed Web of Science ®Google Scholar
• Chaplin S. COVID-19: a brief history and treatments in development. Prescriber. 2020;31:23–28.
   Google Scholar
• Shih H-I, Wu C-J, Tu Y-F, et al. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J. 2020. DOI:10.1016/j.bj.2020.05.021.
   Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with Favipiravir for COVID-19: An open-label control study. Engineering. 2020. [accessed 2020 Sep 15]. DOI:10.1016/j.eng.2020.03.007
   Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.
   Web of Science ®Google Scholar
• Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50:384.
   Web of Science ®Google Scholar
• Shittu MO. Afolami OI improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives—a better synergy for future COVID-19 clinical trials. Infez Med. 2020;28:192–197.
   PubMedGoogle Scholar
• Lundstrom K. Coronavirus pandemic—therapy and vaccines. Biomedicines. 2020;8:109.
   Web of Science ®Google Scholar
• Zhang N, Li C, Hu Y, et al. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020;22:231–235.
   Web of Science ®Google Scholar
• Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Investig. 2020;130:1545–1548.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643–650.
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Bramhachari PV. Dynamics of immune activation in viral diseases. Singapore: Springer; 2020. p. 9–41.
   Google Scholar
• Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33–42.
   PubMed Web of Science ®Google Scholar
• Hershberger E, Sloan S, Narayan K, et al. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study. EBioMedicine. 2019;40:574–582.
   PubMed Web of Science ®Google Scholar
• Gogtay NJ, Munshi R, Ashwath Narayana DH, et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: a phase 2/3, randomized, single-blind, noninferiority, controlled study. Clin Infect Dis. 2018;66:387–395.
   PubMed Web of Science ®Google Scholar
• Sandritter T. Palivizumab for respiratory syncytial virus prophylaxis. J Pediatr Health Care. 1999;13:191–195.
   PubMedGoogle Scholar
• Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9:382–385.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
   PubMed Web of Science ®Google Scholar
• Pinto D, Park Y-J, Beltramello M, et al. Structural and functional analysis of a potent sarbecovirus neutralizing antibody. bioRxivorg. 2020. DOI:10.1101/2020.04.07.023903.
   Google Scholar
• Chen X, Li R, Pan Z, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17:647–649.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxivorg. 2020. DOI:10.1101/2020.05.22.111005.
   Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxivorg. 2020. DOI:10.1101/2020.05.13.092619.
   Google Scholar
• Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115–119.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxivorg. 2020. DOI:10.1101/2020.05.11.088674.
   Google Scholar
• Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010–1014.
   PubMed Web of Science ®Google Scholar
• Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci U S A. 2014;111:5147–5152.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018.
   PubMed Web of Science ®Google Scholar
• Sharpe H, Gilbride C, Allen E, et al. The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology. 2020;160:223–232.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Laboratory testing for coronavirus disease (‎‎‎‎COVID-19)‎‎‎‎ in suspected human cases: interim guidance. World Health Organization.  [accessed 2020 Sep 15]. Available from: https://apps.who.int/iris/handle/10665/331501. License: CC BY-NC-SA 3.0 IGO
   Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020. DOI:10.1056/NEJMoa2022483.
   Web of Science ®Google Scholar
• A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19 - full text view - ClinicalTrials.Gov [Internet]. Clinicaltrials.gov. [ cited 2020 Sep 12].
   Google Scholar
• He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324:773–781.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345–351.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. bioRxiv. 2020. DOI:10.1101/2020.06.30.20142570.
   PubMedGoogle Scholar
• Trial A. Investigating the safety and effects of one BNT162 vaccine against COVID-19 in healthy adults - full text view - ClinicalTrials.Gov [Internet]. Clinicaltrials.gov. [ cited 2020 Sep 12].
   Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020. DOI:10.1016/S0140-6736(20)31866-3.
   Web of Science ®Google Scholar
• Clinical trial of efficacy, safety, and immunogenicity of gam-covid-vac vaccine against COVID-19 - full text view - ClinicalTrials.Gov [Internet]. Clinicaltrials.gov. [ cited 2020d Sep 12].
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxivorg. 2020. DOI:10.1101/2020.05.13.093195.
   Google Scholar
• Clinical Trials Register [Internet]. Clinicaltrialsregister.eu. [cited 2020 Sep 12]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB
   Google Scholar
• Phase III double-blind, placebo-controlled study of AZD1222 for the prevention of COVID-19 in adults - full text view - ClinicalTrials.Gov [Internet]. Clinicaltrials.gov. [ cited 2020o Sep 12].
   Google Scholar
• Riley S, Ainslie KEC, Eales O, et al. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study. medRxiv. 2020. DOI:10.1101/2020.07.10.20150524.
   Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics,comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052.
   PubMed Web of Science ®Google Scholar
• Pollan M, Perez-Gomez B, Pastor-Barriuso R, et al. Prevalance of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–544.
   Web of Science ®Google Scholar
• Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv. 2020. DOI:10.1101/2020.07.09.20148429.
   Google Scholar
• Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol. 2020;92:512–517.
   PubMed Web of Science ®Google Scholar
• Edridge A. Coronavirus protective immunity is short-lasting. medRxiv. 2020. DOI:10.1101/2020.05.11.20086439.
   Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.
   PubMed Web of Science ®Google Scholar
• Li CK, Wu H, Ma S, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181:5490–5500.
   PubMed Web of Science ®Google Scholar
• Kissler SM, Tedijanto C, Goldstein E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the post-pandemic period. Science. 2020;368:860–868.
   PubMed Web of Science ®Google Scholar
• Korber B, Fischer WM, Gnanakaran S, et al.Tracking changes in SARS-CoV-2 spike: evidence that D614G Increases Infectivity of the COVID-19 virus. Cell. 2020. DOI:10.1016/j.cell.2020.06.043
   PubMed Web of Science ®Google Scholar
• Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GI- SAID’s innovative contribution to global health. Glob Chall. 2017;1: 33–46.
   PubMedGoogle Scholar
• Tang X-C, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA. 2014;111:E2018–E2026.
   PubMed Web of Science ®Google Scholar
• Sui J, Aird DR, Tamin A, et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog. 2008;4:e1000197.
   PubMed Web of Science ®Google Scholar
• Young BE, Fong S-W, Chan Y-H, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020. DOI: 10.1016/S0140-6736(20)31757-8.
   Web of Science ®Google Scholar
• Zhang Y, Zhang J, Chen Y, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I. bioRxiv. 2020. DOI:10.1101/2020.05.24.111823.
   Google Scholar
• van Dorp L, Richard D, Tan CC, et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. bioRxiv. 2020. DOI:10.1101/2020.05.21.108506.
   Google Scholar
• Su YCF, Anderson DE, Young BE, et al. Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2. MBio. 2020;11:e01610–20.
   PubMed Web of Science ®Google Scholar
• Gong Y-N, Tsao K-C, Hsiao M-J, et al. SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East. Emerg Microbes Infect. 2020;9:1457–1466.
   PubMed Web of Science ®Google Scholar